IP Library › Granted Patent US 12,245,936
Granted Patent B2
US 12,245,936 · App. 18/587,117 · Granted Mar 11, 2025

Stent structures for use with valve replacements

Inventors: Timothy A. Chuter (San Francisco, CA); Blayne A. Roeder (Bloomington, IN); Sharath Gopalakrishnamurthy (Bangalore, IN); Alan R. Leewood (Lafayette, IN)
Assignee: Cook Medical Technologies LLC
A61F2/2418A61F2/2412A61F2220/0016A61F2230/0019A61F2230/0078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,245,936
App. No.
18/587,117
Granted
Mar 11, 2025
Kind
B2
Abstract

The present embodiments provide a medical device for implantation in a patient comprising a stent and a valve. The stent comprises a proximal region comprising a cylindrical shape having a first outer diameter in an expanded state, and a distal region comprising a cylindrical shape having a second outer diameter in the expanded state. The second outer diameter is greater than the first outer diameter. A proximal region of the valve is at least partially positioned within the proximal region of the stent, and the distal region of the valve is at least partially positioned within one of tapered and distal regions of the stent. When implanted, the proximal region of the stent and the proximal region of the valve are aligned with a native valve, and the distal region of the valve is distally spaced-apart from the native valve.

Claims (95)

1. A valve prosthesis comprising:

a substantially cylindrical proximal region;

a distal region;

a tapered region disposed between the proximal and distal regions;

a stent structure;

a supra-annular valve disposed substantially within the tapered region, the supra-annular valve having a proximal end, a distal end, a proximal region, and a distal region;

the stent structure comprising:

a proximal most row of elongate closed cells disposed at least partially in the proximal region, each elongate closed cell having a length, a shape, first and second proximal angled struts having a length, and first and second distal angled struts having a length, wherein the length of a plurality of the first and second distal angled struts is shorter than the length of a plurality of the first and second proximal angled struts;

an intermediate row of elongate closed cells disposed at least partially in the tapered region and at least partially distally of the proximal most row of elongate closed cells

a distal row of elongate closed cells disposed at least partially in the distal region and at least partially distally of the proximal most and second rows of elongate closed cells;

wherein the distal region of the valve tapers inwardly toward a longitudinal axis of the valve prosthesis;

wherein a plurality of cells in the intermediate row of cells have proximal angled struts that are the distal angled struts of a plurality of cells in the proximal most row of cells, and

wherein the plurality of cells in the intermediate row of cells are larger than a plurality of cells in the proximal most row of cells.

2. The valve prosthesis if claim 1 , wherein a strut width of a plurality of struts of the proximal most row of elongate closed cells is different than a strut width of a plurality of struts of at least one elongate closed cell of the intermediate row of elongate closed cells.

3. The valve prosthesis of claim 1 , wherein the length of each of the first and second distal angled struts of the proximal most row of cells is shorter than the length of each of the first and second proximal angled struts of the proximal most row of cells.

4. The valve prosthesis of claim 1 , wherein the stent comprises a flat wire profile.

5. The valve prosthesis of claim 1 , further comprising a covering, wherein the covering extends over a plurality of a proximal apices of the proximal most row of elongate closed cells.

6. The valve prosthesis of claim 1 , further comprising a covering, wherein the covering extends over an interior and an exterior of the elongate closed cells of the proximal most row of cells.

7. The valve prosthesis of claim 1 , wherein the stent structure of the valve prosthesis comprise a first cell having a first shape, a second cell having a second shape different from the first shape, a third cell

having a third shape different from the first and second shapes, and a fourth cell having a fourth shape different from the first, second and third shapes.

8. The valve prosthesis of claim 7 , wherein one of the shapes is generally spade-shaped.

9. A valve prosthesis comprising:

a valve;

a stent structure comprising:

a proximal most row of elongate closed cells each having a length, proximal apices, distal apices, and a plurality of angled strut segments;

a second row of elongate closed cells at least partially distally of the proximal most row, each elongate closed cell of the second row having a length, proximal apices, distal apices, and a plurality of angled strut segments;

a distal most row of elongate closed cells at least partially distally of the second row of elongate closed cells, each elongate closed cell of the distal most row having a length, proximal apices, distal apices and a plurality of angled strut segments;

wherein a plurality of proximal angled strut segments of the proximal most row of elongate stent cells are longer than a plurality of distal angled strut segments of the proximal most row of elongate closed cells;

wherein the valve tapers inwardly from a proximal valve region to a distal valve region;

wherein a proximal end of the stent flares relative to a longitudinal axis of the valve prosthesis;

wherein a plurality of cells in the intermediate row of cells have proximal angled struts that are the distal angled struts of a plurality of cells in the proximal most row of cells, and

wherein the plurality of cells in the intermediate row of cells are larger than a plurality of cells in the proximal most row of cells.

10. The valve prosthesis if claim 9 , wherein a strut width of a plurality of struts of the proximal most row of elongate closed cells is different than a strut width of a plurality of struts of at least one elongate closed cell of the intermediate row of elongate closed cells.

11. The valve prosthesis of claim 10 , wherein the length of each of the first and second distal angled struts of the proximal most row of cells is shorter than the length of each of the first and second proximal angled struts of the proximal most row of cells.

12. The valve prosthesis of claim 9 , wherein the stent comprises a flat wire profile.

13. The valve prosthesis of claim 9 , further comprising a covering, wherein the covering extends over a plurality of a proximal apices of the proximal most row of elongate closed cells.

14. The valve prosthesis of claim 9 , further comprising a covering, wherein the covering extends over an interior and an exterior of the elongate closed cells of the proximal most row of cells.

15. The valve prosthesis of claim 9 , wherein the stent structure of the valve prosthesis comprise a first cell having a first shape, a second cell having a second shape different from the first shape, a third cell

having a third shape different from the first and second shapes, and a fourth cell having a fourth shape different from the first, second and third shapes.

16. The valve prosthesis of claim 15 , wherein one of the shapes is generally spade-shaped.

17. A valve prosthesis comprising:

a substantially cylindrical proximal region;

a distal region;

an intermediate region disposed between the proximal and distal regions, the intermediate region having a taper;

a stent structure;

a valve disposed within the stent structure;

the stent structure comprising:

a proximal most row of elongate closed cells disposed at least partially in the proximal region, each elongate closed cell having a length and a shape;

an intermediate row of elongate closed cells disposed at least partially in the intermediate region and at least partially distally of the proximal most row of elongate closed cells, each elongate closed cell having a length and a shape;

a distal row of elongate closed cells disposed at least partially in the distal region and at least partially distally of the proximal most and second rows of elongate closed cells, each elongate closed cell having a length and a shape;

a covering extending over a plurality of a proximal apices of the proximal most row of elongate closed cells;

wherein each of the elongate closed cells of the proximal most row of elongate closed cells has first and second proximal angled struts having a length and first and second distal angled struts having a length shorter than the length of the first and second proximal angled struts;

wherein the valve is at least partially disposed within the taper;

wherein the proximal region flares relative to a longitudinal axis of the valve prosthesis;

wherein the valve tapers inwardly substantially continuously from the proximal region to a distal end of the valve;

wherein a plurality of cells in the intermediate row of cells have proximal angled struts that are the distal angled struts of a plurality of cells in the proximal most row of cells, and

wherein the plurality of cells in the intermediate row of cells are larger than a plurality of cells in the proximal most row of cells.

18. The valve prosthesis if claim 17 , wherein a strut width of a plurality of struts of the proximal most row of elongate closed cells is different than a strut width of a plurality of struts of at least one elongate closed cell of the intermediate row of elongate closed cells.

19. The valve prosthesis of claim 17 , wherein the length of each of the first and second distal angled struts of the proximal most row of cells is shorter than the length of each of the first and second proximal angled struts of the proximal most row of cells.

20. The valve prosthesis of claim 17 , wherein the stent comprises a flat wire profile.

21. A valve prosthesis comprising:

a substantially cylindrical proximal region;

a distal region;

a tapered region disposed between the proximal and distal regions;

a stent structure;

a supra-annular valve disposed substantially within the tapered region, the supra-annular valve having a proximal end, a distal end, a proximal region, and a distal region;

the stent structure comprising:

a proximal most row of elongate closed cells disposed at least partially in the proximal region, each elongate closed cell having a length, a shape, first and second proximal angled struts having a length, and first and second distal angled struts having a length, wherein the length of a plurality of the first and second distal angled struts is shorter than the length of a plurality of the first and second proximal angled struts;

an intermediate row of elongate closed cells disposed at least partially in the tapered region and at least partially distally of the proximal most row of elongate closed cells

a distal row of elongate closed cells disposed at least partially in the distal region and at least partially distally of the proximal most and second rows of elongate closed cells; and

wherein the distal region of the valve tapers inwardly toward a longitudinal axis of the valve prosthesis.

22. A valve prosthesis comprising:

a valve;

a stent structure comprising:

a proximal most row of elongate closed cells each having a length, proximal apices, distal apices, and a plurality of angled strut segments;

a second row of elongate closed cells at least partially distally of the proximal most row, each elongate closed cell of the second row having a length, proximal apices, distal apices, and a plurality of angled strut segments;

a distal most row of elongate closed cells at least partially distally of the second row of elongate closed cells, each elongate closed cell of the distal most row having a length, proximal apices, distal apices and a plurality of angled strut segments;

wherein a plurality of proximal angled strut segments of the proximal most row of elongate stent cells are longer than a plurality of distal angled strut segments of the proximal most row of elongate closed cells;

wherein the valve tapers inwardly from a proximal valve region to a distal valve region; and

wherein a proximal end of the stent flares relative to a longitudinal axis of the valve prosthesis.

23. A valve prosthesis comprising:

a substantially cylindrical proximal region;

a distal region;

an intermediate region disposed between the proximal and distal regions, the intermediate region having a taper;

a stent structure;

a valve disposed within the stent structure;

the stent structure comprising:

a proximal most row of elongate closed cells disposed at least partially in the proximal region, each elongate closed cell having a length and a shape;

an intermediate row of elongate closed cells disposed at least partially in the intermediate region and at least partially distally of the proximal most row of elongate closed cells, each elongate closed cell having a length and a shape;

a distal row of elongate closed cells disposed at least partially in the distal region and at least partially distally of the proximal most and second rows of elongate closed cells, each elongate closed cell having a length and a shape;

a covering extending over a plurality of a proximal apices of the proximal most row of elongate closed cells;

wherein each of the elongate closed cells of the proximal most row of elongate closed cells has first and second proximal angled struts having a length and first and second distal angled struts having a length shorter than the length of the first and second proximal angled struts;

wherein the valve is at least partially disposed within the taper;

wherein the proximal region flares relative to a longitudinal axis of the valve prosthesis; and

wherein the valve tapers inwardly substantially continuously from the proximal region to a distal end of the valve.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2024
From: CHUTER, TIMOTHY A.
To: COOK MEDICAL TECHNOLOGIES LLC
Reel/Frame 066898/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2024
From: ROEDER, BLAYNE A.; GOPALAKRISHNAMURTHY, SHARATH; LEEWOOD, ALAN R.
To: MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC.
Reel/Frame 066898/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2024
From: MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC.
To: COOK MEDICAL TECHNOLOGIES LLC
Reel/Frame 066898/0772 →
Continuity (6)
Continuation 18154573 · Jan 13, 2023
Continuation 16913434 · Jun 26, 2020
Continuation 15841744 · Dec 14, 2017
Continuation 13286407 · Nov 1, 2011
Provisional Application 61410540 · Nov 5, 2010
Related Publication 20240307174A1 · Sep 19, 2024
References Cited (232)
US 4222126A · Boretos et al. · 1980 [cited by applicant]
US 4994077A · Dobben · 1991 [cited by applicant]
US 5163953A · Vince · 1992 [cited by applicant]
US 5332402A · Teitelbaum · 1994 [cited by applicant]
US 5370685A · Stevens · 1994 [cited by applicant]
US 5397351A · Pavcnik et al. · 1995 [cited by applicant]
US 5755782A · Love et al. · 1998 [cited by applicant]
US 5840081A · Andersen et al. · 1998 [cited by applicant]
US 5855597A · Jayaraman · 1999 [cited by applicant]
US 5855600A · Alt · 1999 [cited by applicant]
US 5938687A · Bouhour et al. · 1999 [cited by applicant]
US 5938697A · Killion et al. · 1999 [cited by applicant]
US 6120534A · Ruiz · 2000 [cited by applicant]
US 6168619B1 · Dinh et al. · 2001 [cited by applicant]
US 6245102B1 · Jayaraman · 2001 [cited by applicant]
US 6254642B1 · Taylor · 2001 [cited by applicant]
US 6258120B1 · Mckenzie et al. · 2001 [cited by applicant]
US 6409756B1 · Murphy · 2002 [cited by applicant]
US 6416544B2 · Sugita et al. · 2002 [cited by applicant]
US 6440164B1 · DiMatteo et al. · 2002 [cited by applicant]
US 6458153B1 · Bailey et al. · 2002 [cited by applicant]
US 6482228B1 · Norred · 2002 [cited by applicant]
US 6494090B1 · Losing et al. · 2002 [cited by applicant]
US 6582462B1 · Andersen et al. · 2003 [cited by applicant]
US 6730118B2 · Spenser et al. · 2004 [cited by applicant]
US 6773453B2 · Ravenscroft · 2004 [cited by applicant]
US 6773454B2 · Wholey et al. · 2004 [cited by applicant]
US 6797000B2 · Simpson et al. · 2004 [cited by applicant]
US 6830584B1 · Seguin · 2004 [cited by applicant]
US 6911040B2 · Johnson et al. · 2005 [cited by applicant]
US 7018406B2 · Seguin et al. · 2006 [cited by applicant]
US 7144421B2 · Carpenter et al. · 2006 [cited by applicant]
US 7192442B2 · Solem et al. · 2007 [cited by applicant]
US 7201772B2 · Schwammenthal et al. · 2007 [cited by applicant]
US 7220274B1 · Quinn · 2007 [cited by applicant]
US 7267686B2 · DiMatteo et al. · 2007 [cited by applicant]
US 7329278B2 · Seguin et al. · 2008 [cited by applicant]
US 7329279B2 · Haug et al. · 2008 [cited by applicant]
US 7331991B2 · Kheradvar et al. · 2008 [cited by applicant]
US 7351256B2 · Hojeibane et al. · 2008 [cited by applicant]
US 7377938B2 · Sarac et al. · 2008 [cited by applicant]
US 7381219B2 · Salahieh et al. · 2008 [cited by applicant]
US 7429269B2 · Schwammenthal et al. · 2008 [cited by applicant]
US 7442204B2 · Schwammenthal et al. · 2008 [cited by applicant]
US 7510574B2 · Le et al. · 2009 [cited by applicant]
US 7544206B2 · Cohn · 2009 [cited by applicant]
US 7556643B2 · Casey, II et al. · 2009 [cited by applicant]
US 7572286B1 · Chen et al. · 2009 [cited by applicant]
US 7591848B2 · Allen · 2009 [cited by applicant]
US 7682390B2 · Seguin · 2010 [cited by applicant]
US 7780726B2 · Seguin · 2010 [cited by applicant]
US 7789909B2 · Andersen et al. · 2010 [cited by applicant]
US 7799072B2 · Greenberg · 2010 [cited by applicant]
US 7806920B2 · Duran · 2010 [cited by applicant]
US 7857845B2 · Stacchino et al. · 2010 [cited by applicant]
US 7892281B2 · Seguin et al. · 2011 [cited by applicant]
US 7914569B2 · Nguyen et al. · 2011 [cited by applicant]
US 7967853B2 · Eidenschink et al. · 2011 [cited by applicant]
US 8016877B2 · Seguin et al. · 2011 [cited by applicant]
US 8080054B2 · Rowe · 2011 [cited by applicant]
US 8092521B2 · Figulla et al. · 2012 [cited by applicant]
US 8167934B2 · Styrc et al. · 2012 [cited by applicant]
US 8206437B2 · Bonhoeffer et al. · 2012 [cited by applicant]
US 8206438B2 · Yang et al. · 2012 [cited by applicant]
US 8348996B2 · Tuval et al. · 2013 [cited by applicant]
US 8728154B2 · Alkhatib · 2014 [cited by examiner]
US 9345572B2 · Cerf · 2016 [cited by examiner]
US 10376359B2 · Essinger et al. · 2019 [cited by applicant]
US 20020055772A1 · McGuckin et al. · 2002 [cited by applicant]
US 20030040792A1 · Gabbay · 2003 [cited by applicant]
US 20030074052A1 · Besselink · 2003 [cited by applicant]
US 20030120333A1 · Ouriel et al. · 2003 [cited by applicant]
US 20030130726A1 · Thorpe et al. · 2003 [cited by applicant]
US 20030176914A1 · Rabkin et al. · 2003 [cited by applicant]
US 20030199967A1 · Hartley et al. · 2003 [cited by applicant]
US 20040044402A1 · Jung et al. · 2004 [cited by applicant]
US 20040055606A1 · Hendricksen et al. · 2004 [cited by applicant]
US 20040117003A1 · Ouriel et al. · 2004 [cited by applicant]
US 20040210304A1 · Seguin et al. · 2004 [cited by applicant]
US 20040236411A1 · Sarac et al. · 2004 [cited by applicant]
US 20040254636A1 · Flagle et al. · 2004 [cited by applicant]
US 20050075725A1 · Rowe · 2005 [cited by applicant]
US 20050085900A1 · Case et al. · 2005 [cited by applicant]
US 20050096736A1 · Osse et al. · 2005 [cited by applicant]
US 20050102018A1 · Carpenter et al. · 2005 [cited by applicant]
US 20050137682A1 · Justino · 2005 [cited by applicant]
US 20050182483A1 · Osborne et al. · 2005 [cited by applicant]
US 20050222674A1 · Paine · 2005 [cited by applicant]
US 20050251251A1 · Cribier · 2005 [cited by applicant]
US 20060149360A1 · Schwammenthal et al. · 2006 [cited by applicant]
US 20060195180A1 · Kheradvar et al. · 2006 [cited by applicant]
US 20060265056A1 · Nguyen et al. · 2006 [cited by applicant]
US 20060276813A1 · Greenberg · 2006 [cited by applicant]
US 20070118209A1 · Strecker · 2007 [cited by applicant]
US 20070123972A1 · Greenberg et al. · 2007 [cited by applicant]
US 20070168013A1 · Douglas · 2007 [cited by applicant]
US 20070173926A1 · Bobo, Jr. et al. · 2007 [cited by applicant]
US 20070213813A1 · Von Segesser et al. · 2007 [cited by applicant]
US 20070239273A1 · Allen · 2007 [cited by applicant]
US 20070244546A1 · Francis · 2007 [cited by applicant]
US 20080039891A1 · McGuckin et al. · 2008 [cited by applicant]
US 20080082166A1 · Styrc et al. · 2008 [cited by applicant]
US 20080208314A1 · Skerven · 2008 [cited by applicant]
US 20080208325A1 · Helmus et al. · 2008 [cited by applicant]
US 20080262593A1 · Ryan et al. · 2008 [cited by applicant]
US 20080275549A1 · Rowe · 2008 [cited by applicant]
US 20090099649A1 · Chobotov et al. · 2009 [cited by applicant]
US 20090125098A1 · Chuter · 2009 [cited by applicant]
US 20090171437A1 · Brocker et al. · 2009 [cited by applicant]
US 20090198324A1 · Orlov · 2009 [cited by applicant]
US 20100063577A1 · Case et al. · 2010 [cited by applicant]
US 20100094411A1 · Tuval et al. · 2010 [cited by applicant]
US 20100168839A1 · Braido et al. · 2010 [cited by applicant]
US 20100256738A1 · Berglund · 2010 [cited by applicant]
US 20100298927A1 · Greenberg · 2010 [cited by applicant]
US 20110208289A1 · Shalev · 2011 [cited by applicant]
US 20120053676A1 · Ku et al. · 2012 [cited by applicant]
US 20120116496A1 · Chuter et al. · 2012 [cited by applicant]
US 20120116498A1 · Chuter et al. · 2012 [cited by applicant]
US 20120130478A1 · Shaw · 2012 [cited by applicant]
US 20120283820A1 · Tseng et al. · 2012 [cited by applicant]
AU 2003234967A1 · 2003 [cited by applicant]
CN 2817764 · 2006 [cited by applicant]
DE 102007045188 · 2008 [cited by applicant]
EP 1264582A2 · 2002 [cited by applicant]
EP 2489331A1 · 2012 [cited by applicant]
EP 2489331B1 · 2017 [cited by applicant]
JP 495434B · 1974 [cited by applicant]
JP 2004500189A · 2004 [cited by applicant]
JP 2005514968A · 2005 [cited by applicant]
JP 2008539985A · 2008 [cited by applicant]
JP 2008541865A · 2008 [cited by applicant]
WO WO0021463A1 · 2000 [cited by applicant]
WO WO2000041652A1 · 2000 [cited by applicant]
WO WO0149213A2 · 2001 [cited by applicant]
WO WO03003943A2 · 2003 [cited by applicant]
WO WO2003003943A2 · 2003 [cited by applicant]
WO WO2005011535A2 · 2005 [cited by applicant]
WO WO2006124649A2 · 2006 [cited by applicant]
WO WO2006127765A1 · 2006 [cited by applicant]
WO WO2008070797A2 · 2008 [cited by applicant]
WO WO2010008549A1 · 2010 [cited by applicant]
WO WO2010096176A1 · 2010 [cited by applicant]
WO WO2010098857A1 · 2010 [cited by applicant]
WO WO2010099032A2 · 2010 [cited by applicant]
WO WO2011025945A1 · 2011 [cited by applicant]
WO WO2011106544A1 · 2011 [cited by applicant]
WO WO2012027487A2 · 2012 [cited by applicant]
WO WO2012039753A2 · 2012 [cited by applicant]
Decision of European Patent Opposition as rendered for EP 11 275 139.1, dated Nov. 14, 2019, 20 pgs. [cited by applicant]
Minutes of the Oral Proceedings before the Opposition Division on Oct. 21, 2019 for EP 11 275 139.1, dated Nov. 14, 2019, 30 pgs. [cited by applicant]
St. Jude Medical, LLC—European Opposition Against Application/Patent No. 11275139.1/ 2489331, dated Apr. 5, 2018, 39 pgs. [cited by applicant]
No. 16, Boudjemline, Younes et al., “Non-surgical aortic valve replacement: History, present, and future perspectives”, from the book [cited by applicant]
No. 17, Cribier, Alain et al., “Clinical experience with the Percutaneous heart valve for treatment of degenerative aortic stenosis”, from the book [cited by applicant]
No. 18, Laborde, Jean-Claude et al., “The CoreValve in the aortic position”, from the book [cited by applicant]
Biotronik AG—European Opposition Against Application/Patent No. 11275139.1/2489331 , dated Apr. 4, 2018, 48 pgs. [cited by applicant]
Grube, Eberhard et al., “Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease”, [cited by applicant]
[cited by applicant]
Jilaihawi et al., “Self-Expanding Percutaneous Aortic Valve Implantation”, [cited by applicant]
Shultz, Carl J. et al., “Geometry and Degree of Apposition of the CoreValve ReValving System With Multislice Computed Tomography After Implantation in Patients With Aortic Stenosis”, [cited by applicant]
Padala, Muralidhar et al., “An Engineering Review of Transcatheter Aortic Valve Technologies”, [cited by applicant]
Popma, Jeffrey J. et al., “TAVI Using the CoreValve Revalving System, an Update on device data and the latest findings.”, [cited by applicant]
Cribier, Alain et al., “Transcatheter Aortic and Mitral Valve Update, The progress and promise of valvular interventions.”, [cited by applicant]
Grube, Eberhard et al., “Percutaneous Aortic Valve Replacement, an update on the current state of the CoreValve device.”, [cited by applicant]
Green, Jacob et al., “Percutaneous Aortic Valve Replacement, an overview of catheter-based applications.”, [cited by applicant]
Dave, Rajesh M. et al, “Aortic Valvuloplasty, The state of the art and an introduction to percutaneous aortic valve technology.”, [cited by applicant]
Feldman, Ted et al., “Prospects for Percutaneous Valve Therapies”, [cited by applicant]
Medgaget, “Medtronic's CoreValve Transcatheter Aortic Valve Replacement System Performs Well in Trial”, May 20, 2009, 2 pgs. [cited by applicant]
Dvir, Danny et al., “Percutaneous Aortic Valve Implantation: Early Clinical Experience and Future Perspectives”, [cited by applicant]
Chiam, Paul T et al., “Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials”, JACC: Cardiovascular Interventions, vol. 1, No. 4, 2008, pp. 341-350. [cited by applicant]
Appeal Brief filed in U.S. Appl. No. 13/286,407, dated Aug. 21, 2014, 37 pgs. [cited by applicant]
Examiner's Answer to Appeal Brief filed in U.S. Appl. No. 13/286,407, dated Dec. 2, 2014, 9 pgs. [cited by applicant]
Reply Brief filed in U.S. Appl. No. 13/286,407, dated Feb. 3, 2015, 9 pgs. [cited by applicant]
Patent Board Decision for U.S. Appl. No. 13/286,407, dated Oct. 26, 2017, 14 pgs. [cited by applicant]
Request for Rehearing of Patent Board Decision, dated Dec. 22, 2017, 16 pgs. [cited by applicant]
Decision of Reconsideration Denied, dated Apr. 4, 2018, 12 pgs. [cited by applicant]
Decision by CAFC, dated Sep. 6, 2018, 2 pgs. [cited by applicant]
Decision of European Patent Opposition for EP 11 275 139.1, dated Nov. 14, 2019, 26 pgs. [cited by applicant]
“Medtronic's Corevalve Shows Subclavian Access Success in Patients Contraindicated for Femoral Approach”, Medical News Today, May 21, 2009, http://www.medicalnewtoday.com/releases/150929.php, last visited Nov. 24, 2011 … [cited by applicant]
“Medtronic's CoreValve Transcatheter Aortic Valve Replacement System Performs Well in Trial”, Medgaget.com article, posted May 20, 2009, http://www.medgadget.com/archives/print/007754print.html, 3 pgs. [cited by applicant]
“Beating Heart Aortic Valve. Replacement: The Future is Here” Ashok Babu, M.D., Department of Surgery, University of Colorado, PowerPoint presentation, 33 pgs. [cited by applicant]
“SESAME Membrane Covered Stent for SVG's”, Steven R. Bailey, M.D., et al., Univeristy of Texas Health Sciences Center at San Antonio, PowerPoint presentation, 33 pgs. [cited by applicant]
“Percutaneous Aortic Valve Implantation Scope of the Problem and Imaging”, E Murat Tuzcu, Cleveland Clinic, 33 pgs. [cited by applicant]
“Percutaneous Implantation of the First Repositionable Aortic Valve Prosthesis in a Patent With Severe Aortic Stenosis”, L. Buellesfeld, et al., Catheter Cardiovasc Interv. Apr. 1, 2008; 71(5): 579-84, 1 pg. [cited by applicant]
Cedars-Sinai Medical Center Prosthetic Heart Valve Information brochure, Cedars-Sinai Medical Center Division of Cardiology, 37 pgs. [cited by applicant]
“Percutaneous Valve Repair and Replacement”, Howard C. Hermann, M.D., University of Pennsylvania Medical Center, PowerPoint presentation, 15 pgs. [cited by applicant]
“Percutaneous Approaches to Aortic Valve Replacement”, Adam M. Brodsky, M.D., Applications in Imaging-Cardiac Interventions, Dec. 2004, 6 pgs. [cited by applicant]
Percutaneous Aortic Valve Implantation: Early Clinical Experience and Future Perspectives:, Danny Dvir, M.D., et al., IMAJ, vol. 11, Apr. 2009, 6 pgs. [cited by applicant]
“Percutaneous Treatment of Aortic Valve Stenosis”, Inder M. Singh, M.D., et al., Cleveland Clinic Journal of Medicine, vol. 75, No. 11, Nov. 2008, 8 pgs. [cited by applicant]
“First Human Case of Retrograde Transcatheter Implantation of an Aortic Valve Prosthesis”, David Paniagua, M.D., et al., Texas Heart Institute Journal, Transcatheter Aortic Valve Prothesis, vol. 32, No. 3, 2005, 6 pgs. [cited by applicant]
“Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials: The Interventionalist Perspective”, Paul T.L. Chiam, et al., J. Am. Coll. Cardiol. Intv. 2008: 1; 341-350,… [cited by applicant]
“Percutaneous Transcatheter Aortic Valve Implantation: Evolution of the Technology”, Paul T.L. Chiam, et al., American Heart Journal, Feb. 2009, 229-42, 14 pgs. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 13/286,407 dated Dec. 20, 2012, 6 pgs. [cited by applicant]
Response to Restriction Requirement for U.S. Appl. No. 13/286,407 dated Jan. 22, 2013, 7 pgs. [cited by applicant]
Office Action for U.S. Appl. No. 13/286,407 dated Feb. 15, 2013, 13 pgs. [cited by applicant]
Applicant Initiated Interview Summary for U.S. Appl. No. 13/286,407 dated Jun. 6, 2013, 3 pgs. [cited by applicant]
Response to Office Action for U.S. Appl. No. 13/286,407 dated Jul. 15, 2013, 13 pgs. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/286,407 dated Sep. 24, 2013, 12 pgs. [cited by applicant]
Examination Report No. 1 in Australia Application No. 2011244968, dated Dec. 23, 2012, 3 pages. [cited by applicant]
Response to Examination Report No. 1 in Australian Application No. 2011244968, dated Oct. 17, 2013, 11 pages. [cited by applicant]
Examination Report No. 2 in Australia Application No. 2011244968, dated Oct. 22, 2013, 4 pages. [cited by applicant]
Response to Examination Report No. 2 in Australian Application No. 2011244968, dated Dec. 20, 2013, 7 pages. [cited by applicant]
Examination Report No. 3 in Australia Application No. 2011244968, dated Jan. 14, 2014, 4 pages. [cited by applicant]
Response to Examination Report No. 3 in Australian Application No. 2011244968, dated Mar. 24, 2014, 6 pages. [cited by applicant]
Notice of Acceptance in Australian Application No. 2011244968, dated Apr. 3, 2014, 3 pages. [cited by applicant]
Partial European Search Report in European Application No. 11275139.1, dated Jun. 29, 2012, 6 pages. [cited by applicant]
Extended European Search Report in European Application No. 11275139.1, dated Oct. 8, 2012, 12 pages. [cited by applicant]
Notice of Loss of Rights for EP11275139.1 dated Jun. 13, 2013, 1 pg. [cited by applicant]
Response to Notice of Loss of Rights for EP11275139.1 dated Aug. 12, 2013, 11 pgs. [cited by applicant]
Intention to Grant in European Application No. 11275139.1, dated Sep. 28, 2016, 6 pages. [cited by applicant]
Office Action, and English language translation thereof, in corresponding Japanese Application No. 2011-242377, dated Sep. 1, 2015, 4 pages. [cited by applicant]
Response to Office Action, and English language translation thereof, in corresponding Japanese Application No. 2011-242377, dated Jan. 29, 2016, 22 pages. [cited by applicant]
Office Action, and English language translation thereof, in corresponding Japanese Application No. 2011-242377, dated Jun. 8, 2016, 8 pages. [cited by applicant]
Response to Office Action, and English language translation thereof, in corresponding Japanese Application No. 2011-242377, dated Oct. 12, 2016, 6 pages. [cited by applicant]
Decision for Patent, and English language translation thereof, in corresponding Japanese Application No. 2011-242377, dated Feb. 21, 2017, 4 pages. [cited by applicant]
Patent Examination Report No. 1 for AU2011244966 dated Dec. 23, 2012, 3 pgs. [cited by applicant]
Response to Patent Examination Report No. 1 for AU2011244966 dated Jan. 22, 2014, 5 pgs. [cited by applicant]
Patent Examination Report No. 2 in Australian Application No. 2011244966, dated Jan. 28, 2014, 4 pages. [cited by applicant]
Response to Patent Examination Report No. 2 in Australian Application No. 2011244966, dated Mar. 21, 2014, 6 pages. [cited by applicant]
Notice of Acceptance in Australian Application No. 2011244966, dated Apr. 2, 2014, 2 pages. [cited by applicant]
Extended European Search Report for European Patent Application No. 11275138.3 dated Jun. 26, 2012, 6 pgs. [cited by applicant]
Response to Written Opinion for European Patent Application No. 11275138.3 filed Jan. 25, 2013, 7 pgs. [cited by applicant]
Intention to Grant in European Application No. 11275138.3, dated Oct. 5, 2016, 7 pages. [cited by applicant]
Decision to Grant a European Patent Pursuant to Aritcle 97(1) EPC in European Application No. 11275138.3, dated Apr. 6, 2017, pages. [cited by applicant]
Updated Intention to Grant in European Application No. 11275138.3, dated Mar. 15, 2017, 7 pages. [cited by applicant]
Office Action, and English language translation thereof, in Japanese Application No. 2011-242624, dated Aug. 4, 2015, 7 pages. [cited by applicant]
Office Action in U.S. Appl. No. 13/286,416, dated Oct. 24, 2013, 7 pages. [cited by applicant]
Response to Office Action in U.S. Appl. No. 13/286,416, dated Feb. 24, 2014, 17 pages. [cited by applicant]
Office Action in U.S. Appl. No. 13/286,416, dated Mar. 26, 2014, 10 pages. [cited by applicant]
Response to Office Action in U.S. Appl. No. 13/286,416, dated Jul. 28, 2014, 17 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2008/012500 mailed Feb. 6, 2009, 15 pgs. [cited by applicant]
Sisman, Mehtap et al., “The Comparison Between Self-Expanding and Balloon Expandable Stent Results in Left Anterior Descending Artery”, International Journal of Angiology, Jan. 2001, pp. 34-40, vol. 10, No. 1, springer … [cited by applicant]